While drugs like Ozempic, Trulicity, and Jardiance are approved for glucose control in type 2 diabetes (T2D), their role in managing type 1 diabetes (T1D) is still under investigation. Semaglutide, known commercially as Ozempic, Wegovy, and Rybelsus, has demonstrated the potential to significantly impact T1D treatment, particularly in newly diagnosed patients.
Understanding the Role of GLP-1 Receptor Agonists
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of drugs that influence blood glucose and obesity through multiple mechanisms. They work by:
- Blocking glucagon release
- Stimulating insulin production
- Slowing gastric emptying
- Increasing satiety
In T2D patients, these actions result in lower blood sugar levels and weight loss.
Historical Perspective: GLP-1 Therapies in T1D
Breakthrough T1D has a long history with GLP-1 medications like Ozempic. Early clinical trials explored the use of older GLP-1 drugs alongside insulin in T1D management. Some studies showed modest improvements in HbA1c, total insulin dose, and weight. However, these benefits were accompanied by side effects like hypoglycemia. Currently, research focuses on the newest, most advanced GLP-1 therapies, such as Ozempic, to determine their effectiveness in improving the health of people living with type 1 diabetes.
Emerging Evidence: Semaglutide's Impact on T1D
Recent research indicates that semaglutide and tirzepatide (Mounjaro) can potentially lower A1c, increase time-in-range, and reduce daily insulin requirements in individuals with T1D. A study from the University at Buffalo, published in the New England Journal of Medicine, reported remarkable findings regarding semaglutide's impact on newly diagnosed T1D patients.
Read also: Choosing the Right Facial Hair
The University at Buffalo Study: A Glimmer of Hope
The study involved 10 patients diagnosed with Type 1 diabetes within the past three to six months. The mean HbA1c level at diagnosis was 11.7, significantly higher than the American Diabetes Association's recommendation of 7 or below.
The patients were initially treated with a low dose of semaglutide while also taking meal-time (bolus) insulin and basal (background) insulin. The semaglutide dosage was gradually increased, and mealtime insulin was reduced to prevent hypoglycemia.
Key Findings:
- Within three months, all patients eliminated mealtime insulin doses.
- Within six months, seven out of ten patients discontinued basal insulin.
- These results were sustained throughout the 12-month follow-up period.
- Patients' mean HbA1c levels decreased to 5.9 at six months and 5.7 at 12 months.
Paresh Dandona, MD, PhD, the study's senior author, noted the surprising and exciting nature of these findings. He suggested that if these results are confirmed in larger studies with extended follow-up, it could represent the most significant advancement in T1D treatment since the discovery of insulin in 1921.
The Mechanism of Action in T1D
Semaglutide mimics the GLP-1 hormone, which is released in the digestive system after eating. This prompts the body to produce more insulin, thereby lowering blood sugar levels. Dandona's earlier work with liraglutide, another GLP-1 receptor agonist, showed some promise in T1D patients. The discovery that newly diagnosed T1D patients often retain approximately 50% of their insulin reserve led to the investigation of semaglutide in this population.
Additional Benefits Observed
Besides reduced insulin dependence and improved HbA1c levels, patients experienced stable blood sugar levels without significant fluctuations. The researchers speculate that semaglutide may also have a protective effect on beta cells, potentially slowing the progression of the autoimmune destruction characteristic of T1D.
Read also: Comprehensive Guide to Fibromyalgia Massage
Real-World Evidence: Semaglutide in Overweight/Obese T1D Patients
A retrospective chart review study evaluated the use of semaglutide in 50 overweight or obese patients with T1D over one year. The study compared these patients to a control group of 50 matched patients not taking weight loss medications.
Key Findings:
- The semaglutide group experienced significantly greater declines in BMI and body weight compared to the control group.
- The semaglutide group showed improvements in HbA1c, CGM glucose SD and coefficient of variation (CV), and an increase in CGM time in range (TIR).
- There was no significant difference in insulin dose changes, time above range (TAR), or time below range (TBR) between the two groups.
The study concluded that semaglutide effectively lowers body weight and BMI and improves glycemic metrics in overweight and obese T1D patients in a real-world setting.
Cautions and Future Directions
Experts emphasize that more extensive research is necessary before widespread changes in treatment recommendations can be made. While the initial results are promising, larger, controlled studies are crucial to confirm semaglutide's efficacy and safety in T1D patients.
Concerns and Considerations
Increased risk of diabetic ketoacidosis (DKA) in this population limits the use of SGLT drugs.
Ongoing Research and Future Studies
Researchers are planning larger, multi-center studies to further evaluate semaglutide's potential in T1D management. These studies will focus on:
Read also: Is the Type O Diet Effective?
- Confirming the findings of the initial studies
- Assessing the long-term effects of semaglutide on beta cell function
- Identifying the optimal patient population for semaglutide therapy
- Evaluating the safety and efficacy of semaglutide in diverse T1D populations